Feasibility of PEG-rhG-CSF in the first-line treatment of diffuse large B-cell lymphoma receiving dose-adjusted EPOCH plus rituximab.
10.3760/cma.j.issn.0253-2727.2020.02.016
- Author:
Hai Ying WANG
1
;
Zhi Hua YAO
;
Shu Na YAO
;
Jun Feng CHU
;
Zheng YAN
;
Ke WANG
;
Yan Yan LIU
Author Information
1. Department of internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Cyclophosphamide;
Doxorubicin;
Etoposide;
Feasibility Studies;
Granulocyte Colony-Stimulating Factor;
Humans;
Lymphoma, Large B-Cell, Diffuse/drug therapy*;
Polyethylene Glycols;
Prednisone;
Recombinant Proteins;
Rituximab;
Vincristine
- From:
Chinese Journal of Hematology
2020;41(2):167-170
- CountryChina
- Language:Chinese
